Shanghai Pharmaceuticals Declares RMB3.50 Final Dividend per 10 Shares for FY2025

Bulletin Express03-30

Shanghai Pharmaceuticals Holding Co., Ltd. (announcement dated 31 March 2026) declared a final ordinary cash dividend of RMB3.50 for every 10 shares for the financial year ended 31 December 2025, subject to shareholder approval at a forthcoming general meeting (date to be announced).

The dividend will be distributed to holders of H shares through Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. Details on the default payment currency, applicable exchange rate, ex-dividend date, record date, latest time for share transfer lodgement, and payment date will be confirmed in subsequent notices.

Withholding tax arrangements: • Resident enterprise shareholders (registered in the PRC) – 10% enterprise income tax will be withheld. • Non-resident individual shareholders whose domicile countries have a treaty rate of 10% or below – 10% individual income tax will be withheld. • Non-resident individual shareholders whose domicile countries have a treaty rate above 20% or no treaty – 20% individual income tax will be withheld. • Mainland individual investors holding H shares through Southbound Trading – 20% individual income tax will be withheld.

No warrants or convertible securities are affected by this dividend declaration.

Board composition at the time of announcement: Executive Directors – Yang Qiuhua, Shen Bo, Li Yongzhong, Dong Ming; Non-executive Director – Zhang Wenxue; Employee Director – Zhao Yong; Independent Non-executive Directors – Gu Zhaoyang, Fok Manson, Wang Zhong, Man Kwan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment